Tumors in children with aggressive gliomas that formed in the spinal cord all exhibited genetic changes that might be able to be targeted therapeutically,…
Glioma
Calidi Biotherapeutics has begun recruiting adults with high-grade glioma for a Phase 1b/2 clinical trial to study the effects of multiple doses of…
The U.S. Food and Drug Administration (FDA) has agreed to a priority review of a Chimerix application seeking accelerated approval of dordaviprone, its oral…
An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
A signaling molecule released by blood vessel cells prompts cancer cells to grow and become resistant to treatment in glioblastoma, an aggressive type of…
The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx, Foundation Medicine’s companion diagnostic test to help identify if patients with pediatric low-grade…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
Recent Posts
- First-in-human trial launches in US to test drug for hard-to-treat AML
- Hearing my mum’s prediagnosis voice boosts me as a caregiver
- High-potency chemo may hurt, not help in myeloma treatment
- Cancer vaccine may extend survival for glioblastoma patients
- Time to cut the rebirthday cake to observe my stem cell transplant